Bramptons Medtronic of Canada has received Health Canada approval to develop a new technology that will help refractory epilepsy patients. The company has received a license for Medtronic Deep Brain Stimulation (DBS) Therapy. DBS therapy for refractory epilepsy delivers controlled electrical pulses to a location inside the brain involved in seizures. We are proud of the expansion of indications to include epilepsy, which will allow more patients to benefit from our DBS therapy, said Lothar Krinke, vice president and general manager of Medtronics neuromodulation division. The Health Canada license was granted as a result of data collected in during a clinical trial. The study evaluated the use of DBS therapy for patients with medically refractory epilepsy with partial-onset seizures. The trial collected data from 110 patients who were implanted with a Medtronic DBS system at 17 centers in the United States. To date, more than 85,000 patients worldwide have received Medtronic DBS therapy. Although not approved for refractory epilepsy in the U.S, it is approved in Europe. The therapy is currently licensed in Canada and approved in other regions including the European Union and the United States, for the treatment of the disabling symptoms of essential tremor, advanced Parkinsons disease … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/cn48wt/case_study_autism) has announced the addition of the "Case Study: Autism Spectrum Disorders - Public Awareness and Physician Detailing will Drive Market Growth" report to their offering. This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway. To date, only two products have gained approval for the treatment of ASDs; Risperdal (risperidone; Johnson & Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals) are both approved in the US for the treatment of irritability associated with autistic disorder. Scope - Examination of key recommendations contained in published treatment guidelines for the management of ASDs. - Overview of the treatment pathway and identification of three key points of influence that may be targeted by pharmaceutical companies. - Discussion of key opportunities and threats facing existing and prospective players in the autism spectrum disorders market. Key Topics Covered: OVERVIEW Originally posted here: Research and Markets: Autism Spectrum Disorders - Public Awareness and Physician Detailing will Drive Market Growth … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/vlhmzc/randd_trends_auti) has announced the addition of the "R&D Trends: Autism Spectrum Disorders - Pipeline Growth Reflects Increasing Interest in Autism" report to their offering. This report reviews the key trends in the autism spectrum disorders pipeline. The analysis is intended to support R&D decision-making by evaluating the dynamics of the pipeline and hypothesizing future treatments of autism spectrum disorders. The autism spectrum disorders (ASDs) market is a challenging one to penetrate; since 2006 only two products have been successful in entering this marketplace: Risperdal (risperidone; Johnson & amp; Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb). However, as additional agents near the market, increasing interest in ASDs has led to a sizable growth in the clinical pipeline. Scope - Overview of drugs in late- and early-stage clinical development for autism spectrum disorders. - Identification of the target product profile for future autism spectrum disorders treatments. - Summary of clinical trial design in autism spectrum disorders including exploration of key endpoints and assessment methodology. - Identification of key challenges associated with the conduct of clinical trials in autism spectrum disorders. - Exploration of future treatment in autism spectrum disorders including the development of personalized treatments and the use … Continue reading →

Public release date: 25-Jun-2012 [ | E-mail | Share ] Contact: Aaron Lohr alohr@endo-society.org 240-482-1380 The Endocrine Society Stroke patients treated who received hormonal treatment, combined with rehabilitation, performed better on functioning and reasoning tests than patients who received rehabilitative therapy alone, a new clinical study from Italy shows. The results will be presented Monday at The Endocrine Society's 94th Annual Meeting in Houston. In the United States, stroke is the fourth-leading cause of death. The disease occurs when a blood vessel to the brain either ruptures (hemorrhagic stroke), or is obstructed by a clot during an ischemic stroke, which is the most common type. Inadequate blood flow prevents oxygen from reaching parts of the brain, which can lead to tissue death and serious long-term disability. The hormone, relaxin, or RLX, is a naturally occurring protein produced by the reproductive organs in men and women, although only women have circulating hormone in the blood, both during ovulation and pregnancy. For years after its discovery in 1926 by the renowned zoologist and reproductive endocrinologist Frederick Hisaw, the hormone's primary role was thought to be that of relaxing the uterus and pelvis for childbirth. More recently, however, research from this study's investigators, … Continue reading →